## **ELOB/ELOC/VHL Complex Recombinant**

Catalog: 100361 Lot: 230322-B

## **Product Information**

Description: Complex of ELOB (Elongin-B), ELOC (Elongin-C) and VHL (von Hippel-Lindau disease

tumor suppressor), expressed individually and affinity purified as a complex. Recombinant human ELOB, full length encompassing amino acids 2-118 (end). This construct contains an N-terminal FLAG-tag. Recombinant human ELOC, full length encompassing amino acids 2-112 (end). This construct contains an N-terminal His-tag (6xHis). Recombinant human VHL, full length encompassing amino acids 2-213 (end).

This construct contains an N-terminal FLAG-tag.

Species: Human

Construct: ELOB (FLAG-2-118(end)) / ELOC (His-2-112(end)) / VHL (FLAG-2-213(end))

Concentration: 0.14 mg/ml Expression System: HEK293 Purity: ≥90%

**Format:** Agueous buffer solution.

Formulated In: 40 mM Tris-HCl, pH 8.0, 110 mM NaCl, 2.2 mM KCl, 20% glycerol, and 3 mM DTT

MW: VHL: 25 kDa; ELOB: 14 kDa; ELOC: 13 kDa

Genbank Accession: VHL: NM\_000551; ELOB: NM\_007108; ELOC: NM\_005648

**Stability:** At least 6 months at -80°C.

Storage: -80°C

**Instructions for Use:** Thaw on ice and gently mix prior to use. DO NOT VORTEX. Perform a quick spin before

opening. Aliquot into small volumes and flash freeze for long term storage. Avoid

multiple freeze/thaw cycles.

Assay Conditions: Assay run according to VHL Binding Assay Kit (BPS Bioscience #78805) with ELOB/ELOC/

VHL Complex titrated at various concentrations. This assay uses fluorescence

polarization to determine the binding of the complex to a fluorescent probe.

**Applications:** Binding studies and screening of binding inhibitors.

Quality Control Data

